patient subgroup...
Age < 65y (younger) Age > 65y cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), pembrolizumab plus ipilimumab , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 1.08 [0.85, 1.37]< 1 0% 1 study (1/-) 26.4 % NA not evaluable crucial - progression or deaths (PFS) 1.06 [0.86, 1.30]< 1 0% 1 study (1/-) 29.0 % NA not evaluable important - objective responses (ORR) 1.00 [0.72, 1.39]> 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - AE (grade 3-4) endpoints 00 Anaemia AE (grade 3-4) 1.14 [0.41, 3.20]< 1 0% 1 study (1/-) 40.0 % NA not evaluable non important - Arthralgia AE (grade 3-4) 2.01 [0.36, 11.05]< 1 0% 1 study (1/-) 21.3 % NA not evaluable non important - Asthenia AE (grade 3-4) 0.25 [0.03, 2.22]< 1 0% 1 study (1/-) 89.3 % NA not evaluable non important - Back pain AE (grade 3-4) 0.50 [0.04, 5.51]< 1 0% 1 study (1/-) 71.4 % NA not evaluable non important - Constipation AE (grade 3-4) 1.00 [0.14, 7.12]< 1 0% 1 study (1/-) 50.1 % NA not evaluable non important - Cough AE (grade 3-4) 0.50 [0.02, 14.89]< 1 0% 1 study (1/-) 65.4 % NA not evaluable non important - Decreased appetite AE (grade 3-4) 6.03 [0.30, 120.98]< 1 0% 1 study (1/-) 12.3 % NA not evaluable non important - Diarrhoea AE (grade 3-4) 10.29 [1.31, 80.96]< 1 0% 1 study (1/-) 1.4 % NA not evaluable non important - Dyspnoea AE (grade 3-4) 0.87 [0.31, 2.43]< 1 0% 1 study (1/-) 60.6 % NA not evaluable non important - Fatigue AE (grade 3-4) 1.51 [0.42, 5.39]< 1 0% 1 study (1/-) 26.5 % NA not evaluable non important - Hypothyroidism AE (grade 3-4) 1.00 [0.06, 16.01]< 1 0% 1 study (1/-) 50.1 % NA not evaluable non important - Increase AST AE (grade 3-4) 2.52 [0.48, 13.09]< 1 0% 1 study (1/-) 13.7 % NA not evaluable non important - Increased ALT AE (grade 3-4) 2.28 [0.69, 7.50]< 1 0% 1 study (1/-) 8.7 % NA not evaluable non important - Nausea AE (grade 3-4) 4.01 [0.18, 89.26]< 1 0% 1 study (1/-) 19.3 % NA not evaluable non important - Pneumonia AE (grade 3-4) 1.36 [0.72, 2.56]< 1 0% 1 study (1/-) 17.2 % NA not evaluable non important - Pneumonitis AE (grade 3-4) 2.21 [0.83, 5.91]< 1 0% 1 study (1/-) 5.6 % NA not evaluable non important - Pruritus AE (grade 3-4) 0.50 [0.04, 5.51]< 1 0% 1 study (1/-) 71.4 % NA not evaluable non important - Pyrexia AE (grade 3-4) 6.03 [0.30, 120.98]< 1 0% 1 study (1/-) 12.3 % NA not evaluable non important - Rash AE (grade 3-4) 16.38 [0.94, 286.59]< 1 0% 1 study (1/-) 2.9 % NA not evaluable non important - Vomiting AE (grade 3-4) 4.03 [0.45, 36.27]< 1 0% 1 study (1/-) 10.8 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.